The size of the Cancer Biomarkers Market in Europe was worth USD 3.73 billion in 2019 and estimated to be growing at a CAGR of 11.2%, to reach USD 6.34 billion by 2024.
Cancer biomarkers are generally biological molecules found in blood, other body fluids, or tissues that are a signal of a normal or abnormal process, or of a stipulation or disease. The cancer biomarkers are used for drug discovery and development, diagnostics, personalized medicine, and therapeutics. The most recent designed biomarkers and their applications give a great benefit in the cancer cases.
The cancer diagnostics market is driven by increasing the commonness of different forms of cancer, growing cancer awareness, support of government initiatives and funding, and a rise in healthcare expenditure. The introduction of non-invasive screening methods and novel diagnostic biomarkers are likely to create new revenue streams and fuel the cancer diagnostics market over the next five years.
As a result of technological advances, Europe is experiencing major growth. Growth is also largely due to the increasing incidence of cancer and the increasing senior population. These are also a major driver of growth in the region's actual healthcare industry. Major European corporations have partnered with other firms to improve the R&D and product development method. The cancer diagnostics market is also driven by rising incidences of various forms of cancer, raising awareness of cancer, supporting government projects and funding, and increasing spending on health care. The implementation of non-invasive screening technologies and new diagnostic biomarkers is likely to generate new revenue streams in the next five years and boost the cancer diagnostics market.
However, vague reimbursement scenario in certain countries and lack of specificity and sensitivity threaten to obstruct the growth of the cancer diagnostics market. The market is limited by high healthcare costs, reimbursement-related issues, and some regulatory policies that hamper market growth. However, the general population's lack of acceptance of the cancer biomarker, unfavorable salaries, and the lack of skilled workers could be some of the major challenges facing the region's sector.
Because of the support created for biomarkers testing and the increasing number of cancer victims in the area, the European market seems to have a huge opportunity to grow in personalized medicine. In addition, the different biomarker types of products and sub-segments prove to be quite profitable for market growth throughout the forecast period.
Europe Cancer Biomarkers Market segmented and sub-segmented into the following categories.
Regionally, Europe accounts for the second-largest share in the Global Cancer Biomarkers Market. Because of technological developments, the European cancer biomarker market is experiencing significant growth.
The market for cancer biomarkers in Germany holds the largest market share in Europe in 2017, followed by the UK. Increasing the prevalence of cancer in this country and the presence of a high-quality healthcare system contributes to its largest share.
The increasing number of patients of cancer, as well as the government's support for research and innovation of biomarkers, are helping the European market to grow. Some of Europe's market-supporting organizations are the European Cancer Research Association, the German Translational Cancer Research Consortium, and the European Breast Cancer Specialist Society.
Some of the Prominent Companies leading the Europe Cancer Biomarkers Market Profiled in the Report are Abbott Laboratories, Agendia Bv, Biocurex Inc., Biomerieux S.A, Biomoda Inc., Astellas Pharma Us Inc., Correlogic Systems Inc., Beckman Coulter Inc., Becton Dickinson and Company, Clarient Inc., Diadexus Inc., Ambrilia Biopharma, Affymetrix Inc. and Aureon Laboratories Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Disease
5.1.1 Introduction
5.1.2 Prostate Cancer
5.1.3 Breast Cancer
5.1.4 Lung Cancer
5.1.5 Colorectal Cancer
5.1.6 Cervical Cancer
5.1.7 Other Cancers
5.1.8 Y-o-Y Growth Analysis, By Disease
5.1.9 Market Attractiveness Analysis, By Disease
5.1.10 Market Share Analysis, By Disease
5.2 Services
5.2.1 Introduction
5.2.2 Sample Preparation
5.2.3 Assay development
5.2.4 Biomarkers validation and testing
5.2.5 Y-o-Y Growth Analysis, By Services
5.2.6 Market Attractiveness Analysis, By Services
5.2.7 Market Share Analysis, By Services
5.3 Application
5.3.1 Introduction
5.3.2 Risk Assessment
5.3.3 Development of molecular diagnostics
5.3.4 Disease diagnosis
5.3.5 Drug discovery
5.3.6 Development and Drug formulation
5.3.7 Y-o-Y Growth Analysis, By Application
5.3.8 Market Attractiveness Analysis, By Application
5.3.9 Market Share Analysis, By Application
5.4 Type
5.4.1 Introduction
5.4.2 Protein Biomarkers
5.4.3 Genetic biomarkers
5.4.4 genetic biomarkers
5.4.7 Y-o-Y Growth Analysis, By Type
5.4.8 Market Attractiveness Analysis, By Type
5.4.9 Market Share Analysis, By Type
5.5 Profiling Technologies
5.5.1 Omics technologies
5.5.1.1 Genomics
5.5.1.2 Proteomics
5.5.1.3 Metabolomics
5.5.1.4 Transcriptomics
5.5.1.5 Pharmacogenomics
5.5.2 Imaging technologies
5.5.3 Immunoassays
5.5.4 Cytogenetics
5.5.5 Bioinformatics
5.5.6 IVD multivariate index assays
5.5.7 Y-o-Y Growth Analysis, By Profiling Technologies
5.5.8 Market Attractiveness Analysis, By Profiling Technologies
5.5.9 Market Share Analysis, By Profiling Technologies
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Disease
6.1.3.3 By Services
6.1.3.4 By Application
6.1.3.5 By Type
6.1.3.6 Profiling Technologies
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Disease
6.1.4.3 By Services
6.1.4.4 By Application
6.1.4.5 By Type
6.1.4.6 Profiling Technologies
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Disease
6.1.5.3 By Services
6.1.5.4 By Application
6.1.5.5 By Type
6.1.5.6 Profiling Technologies
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Agendia Bv
8.3 Biocurex Inc
8.4 Biomerieux S.A.
8.5 Biomoda Inc
8.6 Astellas Pharma Us Inc
8.7 Correlogic Systems Inc
8.8 Beckman Coulter Inc
8.9 Becton
8.10 Dickinson And Company
8.11 Clarient Inc
8.12 Diadexus Inc
8.13 Ambrilia Biopharma
8.14 Affymetrix Inc
8.15 Aureon Laboratories Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
